Alligator Bioscience comments on Henlius update on long-term follow-up data for HLX22

On May 22, 2026 Alligator Bioscience (Nasdaq Stockholm: ATORX) today comments on a recent update shared by Shanghai Henlius Biotech, Inc. regarding long-term follow-up observations from clinical studies of HLX22.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

According to Henlius’ communication, long-term follow-up over more than 39 months indicates that patients treated with HLX22 continue to demonstrate extended progression-free survival (PFS) at the current observation point. The update reflects ongoing follow-up and does not include new numerical efficacy data.

HLX22 is an innovative anti-HER2 monoclonal antibody that has been granted orphan drug designation in both the U.S. and EU for gastric cancer and is being developed by Henlius under a license from AbClon, Inc., following a discovery collaboration which grants Alligator the right to participate in potential future revenues.

"We view Henlius’ update on the long-term follow-up of HLX22 as further evidence of the continued clinical development of the program," said Søren Bregenholt, CEO of Alligator Bioscience. "Sustained follow-up across studies is an important part of building the overall understanding of a molecule’s profile, and we note Henlius’ ongoing efforts to advance HLX22 across multiple indications."
Under the terms of Alligator’s agreement with AbClon, Alligator is entitled to 35% of AbClon’s revenue from its sublicense to Henlius, including potential milestone payments and royalty revenues, which, if HLX22 is successfully developed and approved, could represent a meaningful long-term revenue opportunity for Alligator.

(Press release, Alligator Bioscience, MAY 22, 2026, View Source [SID1234666006])

PharmaEssentia to Present New Clinical Data Supporting the Use of Ropeginterferon Alfa-2b in Essential Thrombocythemia at ASCO and EHA 2026

On May 22, 2026 PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, reported five upcoming presentations at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting and European Hematology Association (EHA) (Free EHA Whitepaper) 2026 Congress. The ASCO (Free ASCO Whitepaper) annual meeting will be held May 29-June 2 in Chicago, and the EHA (Free EHA Whitepaper)2026 Congress will be held June 11-14 in Stockholm, Sweden.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PharmaEssentia will present new analyses from the Phase 3 SURPASS-ET study (NCT04285086) of ropeginterferon alfa-2b in patients with essential thrombocythemia (ET), including two-year outcomes comparing early versus delayed initiation (continuous treatment from baseline vs. initiation following prior anagrelide therapy) and post-hoc analyses of patients who transitioned from anagrelide. Ropeginterferon alfa-2b-njft is currently FDA-approved and marketed as BESREMi for the treatment of adults with polycythemia vera (PV). The use of ropeginterferon alfa-2b-njft for ET is currently still investigational, but it is currently under review by FDA with a PDUFA goal date of August 30, 2026.

Findings from SURPASS-ET demonstrate sustained hematologic control and progressive molecular improvement with longer interferon exposure, with deeper molecular responses and improved long-term disease control observed with earlier initiation. Patients who transitioned from anagrelide showed improved hematologic parameters over 12 weeks, supporting the feasibility of treatment transition. Importantly, estimated progression-free survival (PFS) at 24 months was 76.9% in patients who received ropeginterferon alfa-2b from baseline compared to 43.1% in those with delayed initiation. Together, these data support consideration of earlier ropeginterferon alfa-2b use in high-risk ET following hydroxyurea intolerance or resistance.

PharmaEssentia will also present an integrated analysis of the SURPASS-ET and Phase 2b EXCEED-ET (NCT05482971) trials. The analysis includes 182 patients across both studies and evaluates the consistency of clinical benefit across treatment lines, including treatment-naïve and previously treated populations, as well as across molecular subtypes and ethnicities. Results demonstrated clinically meaningful hematologic and molecular responses in both treatment-naïve and pretreated patients. Efficacy was consistent across driver mutation subtypes, and the presence of additional non-driver mutations did not adversely impact outcomes.

"These findings represent an important step forward in understanding the potential use of interferon-based approaches in essential thrombocythemia," said Ruben Mesa, M.D., co-principal investigator, presenting author, and President of Advocate Health Cancer National Service Line. "Together, these data continue to build on the growing body of evidence supporting the use of ropeginterferon alfa-2b in ET and reinforce its potential role as a meaningful treatment option for patients."

In addition, PharmaEssentia will present real-world data evaluating the association between neutrophil-to-lymphocyte ratio (NLR) and thrombotic risk in 11,809 U.S. veterans with PV. An online-only abstract will also report findings from a meta-analysis evaluating dosing strategies for ropeginterferon alfa-2b in PV, suggesting that a higher initial dose with accelerated titration (HIDAT) may lead to improved early hematologic and molecular response rates compared to lower-dose currently approved regimens.

ASCO
Poster Presentations

Title: Integrated Analysis of the Ropeginterferon alfa-2b Clinical Program in Essential Thrombocythemia to Demonstrate Molecular and Hematologic Responses with Safety Profile Across Treatment Lines, Ethnicities, and Driver Mutation Types
Abstract Number: 6576
Poster: 369
Presenter: Ruben Mesa, M.D.
Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
Date: June 1st
Time: 9-12 pm CDT

Title: Association of neutrophil‑to‑lymphocyte ratio and thrombotic events in US Veterans with Polycythemia vera
Abstract Number: 6578
Poster: 371
Presenter: Ying Wang, PhD
Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
Date: June 1st
Time: 9-12 pm CDT

Published Abstract

Title: Effect of Higher Initial Dose and Accelerated Titration of Ropeginterferon Alfa-2b on Early Hematologic and Molecular Responses in Polycythemia Vera: A Meta-Analysis
Abstract Number: e18592

EHA
Oral Presentation
Title: Early versus Delayed Initiation of Ropeginterferon Alfa-2b in High-Risk Essential Thrombocythaemia: Two-Year Results from the Phase 3 SURPASS-ET Study
Abstract Number: S219
Presenter: Harry Gill, M.D.
Session: Myeloproliferative neoplasms – Clinical
Date: June 13th
Time: 5:15 – 6:30 pm CEST

Poster Presentations

Title: Ropeginterferon alfa-2b Demonstrates Molecular and Hematologic Responses with a Favorable Safety Profile in Essential Thrombocythemia
Abstract Number: PS1986
Presenter: Harry Gill, M.D.
Session: Myeloproliferative neoplasms – Clinical
Date: June 13th
Time: 6:45 – 7:45 pm CEST

Title: Hematologic Control and Improved Safety Following Switch from Anagrelide to Ropeginterferon Alfa-2b in Patients with Essential Thrombocythemia: 12-Week Pre-/Post-Switch Analysis from the SURPASS-ET study
Abstract Number: PF912
Presenter: Lucia Masarova, M.D.
Session: Myeloproliferative neoplasms – Clinical
Date: June 12th
Time: 6:45 – 7:45 pm CEST

(Press release, PharmaEssentia, MAY 22, 2026, View Source [SID1234666022])

ClearNote Health to Present Early Detection Validation Data for Avantect® Pancreatic Cancer Test at 2026 ASCO Annual Meeting

On May 22. 2026 ClearNote Health, a company dedicated to improving early detection for some of the deadliest cancers, reported it will present new multi-cohort validation data for its Avantect Pancreatic Cancer Test at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place in Chicago May 29 – June 2.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ASCO attendees are invited to meet with ClearNote Health’s scientific and medical leadership team, including newly appointed Chief Medical Officer Jeffrey Venstrom, MD, and Chief Scientific Officer Samuel Levy, PhD, to discuss the company’s latest clinical data, strategic commercialization progress, and vision for advancing early cancer detection.

"Pancreatic cancer remains one of the most lethal malignancies because it is often diagnosed too late for curative intervention," said Dr. Venstrom. "We are excited to share new validation data at ASCO (Free ASCO Whitepaper) demonstrating the strong performance of our Avantect Pancreatic Cancer Test among individuals with elevated risk. This test complements existing diagnostic and risk assessment strategies and provides clinically actionable insights when earlier detection can make the greatest difference."

During the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting, ClearNote Health will present results from an independent validation cohort of 1,445 individuals with multiple risk factors, including type 2 diabetes, family history, and genetic predisposition to pancreatic cancer. In this cohort, the Avantect Pancreatic Cancer Test demonstrated industry-leading performance, achieving 82.6% overall sensitivity, 76.8% sensitivity for early-stage (Stage I–II) disease, and 97.5% specificity. Two additional validation cohorts totaling 338 individuals showed consistently robust performance of Avantect in individuals enriched for new onset type 2 diabetes, further supporting its performance in clinically relevant populations with elevated risk.

"Our enhanced Avantect test combines a rich set of signals from epigenomic, fragmentomic, and genotyping sources in concert with glycan-specific measures into a multimodal cancer detection model. The precision of cancer detection achieved with our Avantect test is reflected in these validation results," said Dr. Levy.

Featured Presentation

Multi-cohort validation of a multi-analyte liquid biopsy test for early-stage pancreatic cancer detection
Abstract / poster number: 4139 / 122
Presenter: Anna Bergamaschi, PhD, ClearNote Health
Session: Gastrointestinal Cancer
Location: Hall A – Posters and Exhibits
Date and time: Saturday, May 30, 2026, 9:00 am – 12:00 pm CDT

Designed as a simple blood test, the Avantect Pancreatic Cancer Test is intended for patients with known genetic predispositions, a family history of pancreatic cancer, or those age 50 or older who have been newly diagnosed with type 2 diabetes. By evaluating multiple cancer-associated signals together, ClearNote Health’s approach provides meaningful context for care discussions. The next-generation test is being used in the Surveillance of pAncreatic health aFter diabEtes Diagnosis (SAFE-D) study led by the NHS in the UK — one of the world’s largest projects evaluating pancreatic cancer detection in individuals with new-onset diabetes. The test is also being incorporated into the international Pancreatic Cancer Early Detection (PRECEDE) Consortium, a global multi-center effort focused on advancing earlier diagnosis and risk-stratified screening for people with familial or genetic risk for pancreatic cancer.

To learn more about ClearNote Health’s planned activities at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting or to schedule a meeting, please visit View Source

(Press release, ClearNote Health, MAY 22, 2026, View Source [SID1234666023])

BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

On May 22, 2026 BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, reported that two abstracts featuring GLIX1 will be published at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2026 Annual Meeting, which is being held May 29-June 2, 2026, in Chicago, IL.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2026 Annual Meeting
May 22, 2026
PDF Version
TEL AVIV, Israel and OSLO, Norway, May 22, 2026 /PRNewswire/ — BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, reported that two abstracts featuring GLIX1 will be published at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2026 Annual Meeting, which is being held May 29-June 2, 2026, in Chicago, IL.

BioLineRx Ltd. Logo

Hemispherian AS Logo
"We are very pleased to have the opportunity to feature these compelling GLIX1 data during this year’s ASCO (Free ASCO Whitepaper) Annual Meeting," stated Philip Serlin, Chief Executive Officer of BioLineRx. "Our first-in-human Phase 1/2a clinical trial of GLIX1 in glioblastoma (GBM) was initiated in March, and we are excited to highlight the wealth of pre-clinical data that both support its novel mechanism of action and provide strong rationale for the development of GLIX1 in GBM as well as in other cancers."

Dr. Adam Robertson, Ph.D., Chief Scientific Officer of Hemispherian AS, added, "Following years of dedicated research and discovery into the field of the cellular DNA damage response, we are very excited with the progress of the GLIX1 development program to date. This oral small molecule enhances TET2 activity, a novel mechanism of action designed to induce tumor-selective DNA strand breaks in a broad range of cancers. The ASCO (Free ASCO Whitepaper) abstracts describe the potential of GLIX1 as monotherapy as well as possible therapeutic synergies when combined with PARP inhibitors."

Abstract Details:

Title: GLIX1: A first-in-class oral molecule targeting the DNA damage response by restoring TET2 activity

Abstract Number: e14072

Session Title: Publication Only: Central Nervous System Tumors

This abstract describes GLIX1, a first-in-class oral small molecule designed to target the DNA damage response by restoring activity of the TET2 enzyme, which is typically suppressed in cancer. TET2 plays a key role in DNA demethylation, and its inhibition in tumors contributes to abnormal DNA hypermethylation. By reactivating TET2, GLIX1 increases DNA demethylation and triggers excessive base excision repair, leading to the accumulation of single-strand DNA breaks that ultimately convert into lethal double-strand breaks in cancer cells. This mechanism is applicable across tumor types and is particularly relevant in glioblastoma, where TET2 activity is significantly impaired.

Preclinical studies have shown that GLIX1 effectively increases TET2 activity and downstream 5hmC production in biochemical assays, cell models, and in vivo animal systems. The high potency of GLIX1 was observed in vitro in a broad range of cancer cell lines. The drug demonstrated strong antitumor activity in multiple glioblastoma xenograft models (including U87-MG and SNB-19) and was able to penetrate the brain efficiently after oral dosing, with brain exposure corresponding to 68-85% of plasma levels in mice. Safety studies in animals indicated that GLIX1 is well-tolerated even at the highest feasible doses tested: 2000mg/kg in rats and 1000mg/kg in dogs. These findings, together with the fact that high-grade gliomas are characterized by markedly reduced genomic levels of 5hmC compared with normal tissue, reflecting impaired TET2 activity and potential therapeutic vulnerability, support clinical evaluation of GLIX1 in GBM as the first indication. A first-in-human Phase 1/2a clinical trial is currently enrolling (NCT07464925).

Title: Synergistic antitumor activity of GLIX1, a small molecule TET2 activator, in combination with PARP inhibition across multiple cancers

Abstract Number: e13129

Session Title: Publication Only: Breast Cancer—Metastatic

Summary: This abstract explores the potential of combining GLIX1, a small-molecule activator of TET2, with PARP inhibitors (PARPi) to enhance cancer cell killing. PARP normally detects and helps repair single-stranded DNA breaks, and PARP inhibitors work by blocking this repair process, leading to cell death, particularly in tumors already deficient in homologous recombination (HR) repair. However, their effectiveness is limited in many cancers that retain this repair capability. GLIX1 is designed to increase tumor-selective DNA damage by restoring TET2 activity, which generates single-stranded DNA breaks through base excision repair. When paired with PARP inhibition, these breaks are not properly repaired, creating a mechanistic basis for enhanced antitumor activity.

In preclinical in vitro studies across a wide range of cancer cell lines, the combination of GLIX1 with multiple PARP inhibitors produced strong and consistent cytotoxic effects, including in tumor types typically less responsive to PARP inhibition. This synergy was observed across different PARP inhibitors with varying properties, suggesting a class-wide effect rather than dependence on a specific agent. Overall, the findings provide a compelling mechanistic rationale for combining GLIX1 with PARP inhibitors and warrant further investigation of this strategy across diverse cancers.

About Glioblastoma

Glioblastoma is the most common primary brain tumor and remains one of the most aggressive and treatment-resistant cancers, urgently in need of breakthrough innovations and more effective treatment. The standard of care for newly diagnosed GBM established since 2005 consists of surgery, followed by radiotherapy and treatment with temozolomide (TMZ), with no established standard of care for recurrent GBM. However, patients with unmethylated MGMT1 promoter status (who represent more than half of all GBM patients) have demonstrated a limited response to TMZ.

About GLIX1

GLIX1 is a first-in-class, orally administered, brain penetrating, small molecule activator of the Ten-Eleven Translocation 2 (TET2) pathway that is commonly inhibited in cancer. Activating the novel TET2 pathway by GLIX1 overwhelms the DNA repair capacity of cancer cells, resulting in apoptotic cancer cell death.

About the Phase 1/2a Trial with GLIX1

The Phase 1/2a trial is an open-label, multicenter trial. Part 1 of the trial is a dose escalation study where patients receive GLIX1 daily as monotherapy. This part is expected to recruit up to 30 patients with recurrent and progressive GBM and other high-grade gliomas. The primary objective is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy. Updates to the Phase 1/2a trial are anticipated during H2 2026, with full results on the dose escalation part expected in 2027.

The Phase 2a expansion part of the trial is planned to include additional indications, including newly diagnosed GBM, as well as select cancers, with GLIX1 as monotherapy or in combination with standard of care (including in combination with PARP inhibitors). These cohorts are expected to identify preliminary efficacy, PD assessments and dose optimization data, serving as the basis for a rapid and effective advanced clinical development plan.

For more information on the Phase 1/2a trial, please visit NCT07464925.

(Press release, BioLineRx, MAY 22, 2026, View Source [SID1234666008])

SAGA Diagnostics to Present Data on Ultrasensitive Pathlight™ MRD Test in Breast, Colon, and Rectal Cancers at ASCO 2026

On May 22, 2026 SAGA Diagnostics, a pioneer in ultrasensitive molecular residual disease (MRD) detection and precision oncology, reported that the company and key collaborators will present data from three abstracts at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2026 Annual Meeting, taking place May 29 to June 2 in Chicago.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key poster presentations highlight the expanding body of evidence supporting Pathlight, SAGA’s tumor-informed structural variant (SV)-based circulating tumor DNA (ctDNA) platform, across both metastatic and localized settings. Retrospective analysis of PADA-1 samples will explore ctDNA kinetics during first-line therapy in metastatic breast cancer, while the real-world CITCCA cohort will evaluate Pathlight in colon and rectal cancer, through assessment of ctDNA clearance, recurrence risk, and outcomes in localized disease.

"As MRD testing becomes increasingly important in oncology, clinicians need assays capable of detecting patient-specific molecular residual disease at the lowest possible levels across a broad range of clinical settings," said Wendy Levin, MD, MS, Chief Clinical Officer at SAGA Diagnostics. "The data being presented at ASCO (Free ASCO Whitepaper) 2026 further highlight the potential of Pathlight’s ultrasensitive tumor-informed ctDNA approach to support treatment monitoring, recurrence assessment, and longitudinal disease surveillance across both metastatic and localized cancers."

Key SAGA Diagnostics Presentations During ASCO (Free ASCO Whitepaper) 2026:

Abstract Title

Presentation Details

ctDNA kinetics throughout first-line AI and palbociclib using a tumor-informed structural variant-based ctDNA assay: retrospective analysis of PADA-1 samples

Abstract: 3050

Poster: 187

Date: May 30, 2026

Time: 1:30 – 4:30 PM

Speaker: Luc Cabel, Institut Curie

Circulating Tumor DNA Clearance of Adjuvant Chemotherapy in Localized Colorectal Cancer Using an Ultrasensitive Structural Variant–Based Assay

Abstract: 3625

Poster: 392

Date: May 30, 2026

Time: 9:00 – 12:00 PM

Speaker: Cecilia Merk, MD, Karolinska Institutet

Localized Rectal Cancer Outcomes Predicted by ctDNA Analysis Using a Novel Ultrasensitive Structural Variant (SV)-based Method

Abstract: 3619

Poster: 386

Date: May 30, 2026

Time: 9:00 – 12:00 PM

Speaker: Cecilia Merk, MD, Karolinska Institutet

The full abstracts for SAGA Diagnostics at ASCO (Free ASCO Whitepaper) 2026 can be found here.

(Press release, SAGA Diagnostics, MAY 22, 2026, View Source [SID1234666024])